Alzheimer's Solutions
|
Alzheimer’s disease currently afflicts as many as 5.3 million people in the United States. By 2029, the number of new cases is expected to exceed 615,000 and by 2050 that number could reach nearly 960,000. The effects of the disease are not only emotionally taxing but financially crippling. Alzheimer’s disease accounts for a total of $148 billion in costs to Medicare, Medicaid and businesses. Alzheimer’s disease is about much more than numbers. It’s about people, and the loss of their independence, their memory, and their identity. It’s about American families watching their loved ones suffer, while a cure seems out of reach. |
Goals
We must accelerate and focus national efforts, reengineer dementia care delivery, and ultimately prevent Alzheimer’s disease. This process includes changes to several large government entities including redesigning the budget to be built around science, reforming the FDA in order to streamline the process and bring new drug discoveries to market swiftly and safely, and the development of better funding, education and outreach to communities and individuals.
Priorities
- Encourage more appropriation dollars are spent wisely on research for all brain sciences.
- Help individuals to understand the signs of dementia and Alzheimer’s disease.
- Promote science-based budgeting on the national level.
- Overhaul the FDA to make the pipeline of clinical trials and approvals more expedient.
- Seek and find global collaboration on a disease that has no borders.
- Educate physicians to look early signs of the disease and tackle it from the beginning.
- Find how to prevent the disease and ease the suffering of millions, both patients and the caregivers.
To learn more about the project, or to become actively involved in this new phase of outreach and promotion for a solution, please contact Michelle Stein, Executive Director, at 202.375.2063 or mstein@gingrichgroup.com.
